Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

It's all about IP and competition. We'll see.

This is a very valuable asset that Momenta has acquired. It's very hard to put a price on it until we see more action from the FDA on how it's going to handle the Bio's.

Amgen has already received approval for a substitute Humira but it only awarded them something like 6 of the nearly dozen indications that Humira has approval for. Childhood disease is limited.

Humira cover a huge market but the biosim situation is confusing at best. I expect to see Momenta sell this off in the future.

I'm still scratching my head why Shire would abandon this at this stage of the game. But again with Momenta I've scratched my head so often I have a bald spot down the middle. I do expect Momenta will have a drug to fix this situation.